Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NMRA-323511

Small molecule · developed by Neumora Therapeutics

Phase 1 Most advanced trial (none active)
NMRA Developer
1 Registered trials

What is NMRA-323511?

NMRA-323511 is an oral agent studied in Alzheimer's disease and in healthy elderly participants.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Neumora Therapeutics, Inc. (NMRA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06546995 Phase 1 Alzheimer's Disease Completed NMRA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer's DiseaseHealthy Elderly

More from Neumora Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NMRA page.

Follow NMRA, the company behind NMRA-323511

See NMRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NMRA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.